Aubrey Capital Management LTD Dexcom Inc Transaction History

Aubrey Capital Management LTD

$247 Million
Q4 2024

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 05, 2024	SELL	$75.49 - $124.16 $45,294 - $74,496	-600 Reduced 2.04%	28,860 $3.58 Million
Q3 2023 Oct 31, 2023	SELL	$86.06 - $137.93 $1.29 Million - $2.07 Million	-15,000 Reduced 33.74%	29,460 $2.75 Million
Q2 2023 Aug 14, 2023	SELL	$112.47 - $130.98 $427,386 - $497,723	-3,800 Reduced 7.87%	44,460 $5.71 Million
Q4 2022 Feb 08, 2023	SELL	$84.98 - $122.67 $305,928 - $441,612	-3,600 Reduced 6.94%	48,260 $5.46 Million
Q3 2022 Oct 25, 2022	SELL	$76.35 - $94.18 $328,305 - $404,974	-4,300 Reduced 7.66%	51,860 $4.18 Million
Q2 2022 Aug 16, 2022	BUY	$67.99 - $132.89 $2.77 Million - $5.41 Million	40,720 Added 263.73%	56,160 $4.19 Million
Q1 2022 May 05, 2022	SELL	$94.08 - $130.2 $470,400 - $651,000	-5,000 Reduced 24.46%	15,440 $7.9 Million
Q2 2021 Aug 12, 2021	SELL	$80.99 - $107.93 $121,484 - $161,895	-1,500 Reduced 6.84%	20,440 $2.18 Million
Q3 2020 Oct 29, 2020	SELL	$95.51 - $112.95 $38,204 - $45,180	-400 Reduced 1.79%	21,940 $2.26 Million
Q2 2020 Aug 10, 2020	SELL	$62.68 - $105.34 $752,160 - $1.26 Million	-12,000 Reduced 34.94%	22,340 $2.26 Million
Q1 2020 Apr 30, 2020	SELL	$47.79 - $75.63 $172,044 - $272,268	-3,600 Reduced 9.49%	34,340 $2.31 Million
Q4 2019 Feb 13, 2020	BUY	$36.62 - $57.29 $124,507 - $194,786	3,400 Added 9.84%	37,940 $8.3 Billion
Q3 2019 Nov 04, 2019	BUY	$35.53 - $43.8 $390,830 - $481,799	11,000 Added 46.73%	34,540 $1.29 Million
Q2 2019 Aug 22, 2019	BUY	$27.84 - $38.92 $119,405 - $166,927	4,289 Added 22.28%	23,540 $3.53 Billion
Q1 2019 May 14, 2019	BUY	$28.07 - $38.18 $540,375 - $735,003	19,251 New	19,251 $0

Others Institutions Holding DXCM

# of Institutions

1,072

Shares Held

339M

Call Options Held

6.74M

Put Options Held

6.33M

View Full List

About DEXCOM INC

Ticker DXCM
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 386,257,984
Market Cap $34.4B
Description
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM ...

More about DXCM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Aubrey Capital Management LTD, based on Form 13F filings with the SEC.

News

Stay updated on Aubrey Capital Management LTD with notifications on news.

Account